On Sept. 23–25, the ACR will once again hold its annual Advocates for Arthritis fly-in event in Washington, D.C. Held in conjunction with the ACR’s Advocacy 101 course, the fly-in is a great way for members and their patients to learn about issues important to the practice of rheumatology and have the opportunity to actively…
Mary Beth Nierengarten is a writer, editor and journalist with over 25 years of medical communications experience. She is a regular contributor to a number of online and print publications and writes in most clinical areas, as well as on health policy and economic issues. She lives in Minneapolis and can be reached at [email protected].
Articles by Mary Beth Nierengarten
ACR/ARHP Heads to D.C. for Advocacy Leadership Conference
ACR/ARHP leaders are once again heading to Washington, D.C., to advocate for legislation important to rheumatologists and their patients. On May 16–18, more than 100 representatives of the ACR Board of Directors, Executive Committee, Government Affairs Committee, RheumPAC, Committee on Rheumatologic Care, Insurance Subcommittee and Affiliate Society Council and others will talk to members of…
Study Urges Caution with Steroid Injections for Hip Osteoarthritis
For patients with hip osteoarthritis (OA), pain management and maintaining function are primary therapy goals. Current guidelines offer recommendations on nonpharmacologic and pharmacologic approaches to addressing these issues in hip OA. For patients in whom pharmacologic management is considered, the use of intra-articular steroid injections is one option. In its 2012 guidelines (the most current…
Study Finds Pedometers Reduce Fatigue in RA Patients
For people with rheumatoid arthritis (RA), fatigue can be a debilitating symptom that interferes with daily life and significantly reduces quality of life. Managing fatigue can be difficult; it is linked to disease activity and a host of other conditions that commonly accompany RA, such as depression, sleep problems and obesity. A new study, however,…
Chronic Pain Research Probes Neurologic Pain Pathways, Biomarkers
With the aid of increasingly sophisticated neuroimaging technology, research into how the brain activates and changes in patients with chronic pain is delivering fascinating information that will hopefully pave the way to tailored, individual treatment of chronic pain. Over the past several years, data from neuroimaging studies have provided a new understanding of what occurs…
ACR’s 2017 Advocacy Successes
In the ever-changing healthcare delivery landscape, the ACR continues to go to work on behalf of its members to ensure public policies encourage delivery of high-quality rheumatology care and treatment. With stepped-up efforts to meet with federal administrative and Congressional representatives, and broadened coalitions of partners to strengthen advocacy for key issues important to the…
ACR Continues to Press CMS to Make Changes to E/M Codes
On Dec. 8, 2017, members of the Cognitive Care Alliance (CCA)—of which the ACR is a leading member—met with members of Congress on the Hill and representatives from the Centers for Medicare and Medicaid Services (CMS) to discuss ongoing concerns about the inadequacy of existing evaluation and management (E/M) codes to properly remunerate cognitive services…
Update on ACR’s Rheumatology-Specific APM
Efforts by the ACR to develop a rheumatology-specific alternative payment model (APM) are well under way. The first draft proposal was approved by the ACR Board of Directors in November and presented to the rheumatology community during the 2017 ACR/ARHP Annual Meeting in San Diego. The ACR is pursuing the development of a rheumatology-specific APM…
Research Targets Interferon Alpha in New Treatment Approach for CNS Lupus
RETRACTED Editor’s note: The study this article reported on was retracted by the researchers. Key aspects could not be replicated, and they said, “Most importantly, the findings from behaviour studies and sequencing of microglia isolated from 564Igi autoimmune mice as shown in Figs. 1a, b, d and 3a, b are not substantiated upon further analysis…
Rheumatology Drug Updates: Biosiomilar to Adalimumab Receives FDA Approval; plus Updates on Baricitinib, Tofacitinib, Bimekizumab
FDA Approves Adalimumab-adbm On Aug. 29, the FDA approved Cyltezo (adalimumab-adbm), a biosimilar to Humira (adalimumab).1 Cyltezo was approved as a prefilled syringe to treat multiple chronic inflammatory diseases, including moderate to severe active RA, active psoriatic arthritis and ankylosing spondylitis, and moderate to severe plaque psoriasis. The treatment has also been approved for moderate…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 16
- Next Page »